Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

High-throughput mutational analysis of the human cancer genome.

Ma PC, Zhang X, Wang ZJ.

Pharmacogenomics. 2006 Jun;7(4):597-612. Review.

PMID:
16753007
2.

Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim SH, Lee JY, Yoo NJ, Lee SH.

Clin Cancer Res. 2006 Jan 1;12(1):57-61.

3.

Identification of cancer genes by mutational profiling of tumor genomes.

Benvenuti S, Arena S, Bardelli A.

FEBS Lett. 2005 Mar 21;579(8):1884-90. Review.

4.
5.

Mutational analysis of the tyrosine phosphatome in colorectal cancers.

Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE.

Science. 2004 May 21;304(5674):1164-6.

6.

Genome-wide mutational analyses of breast and colorectal cancers.

Lin J, Sjöblom T.

Discov Med. 2007 Feb;7(37):13-9.

7.

High frequency of mutations of the PIK3CA gene in human cancers.

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE.

Science. 2004 Apr 23;304(5670):554. Epub 2004 Mar 11. No abstract available.

8.

Somatic mutations in human cancer: insights from resequencing the protein kinase gene family.

Futreal PA, Wooster R, Stratton MR.

Cold Spring Harb Symp Quant Biol. 2005;70:43-9.

PMID:
16869737
9.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

10.

Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer.

Laczmanska I, Sasiadek MM.

Acta Biochim Pol. 2011;58(4):467-70. Epub 2011 Dec 6. Review.

11.

Mutational analysis of gene families in human cancer.

Bardelli A, Velculescu VE.

Curr Opin Genet Dev. 2005 Feb;15(1):5-12. Review.

PMID:
15661527
12.

Absence of tyrosine kinase mutations in Japanese colorectal cancer patients.

Shao RX, Kato N, Lin LJ, Muroyama R, Moriyama M, Ikenoue T, Watabe H, Otsuka M, Guleng B, Ohta M, Tanaka Y, Kondo S, Dharel N, Chang JH, Yoshida H, Kawabe T, Omata M.

Oncogene. 2007 Mar 29;26(14):2133-5. Epub 2006 Oct 2.

PMID:
17016444
13.

Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer.

Chen Z, Feng J, Buzin CH, Liu Q, Weiss L, Kernstine K, Somlo G, Sommer SS.

PLoS One. 2009 Sep 28;4(9):e7220. doi: 10.1371/journal.pone.0007220.

14.

Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology.

Holden JA, Willmore-Payne C, Layfield LJ.

Exp Mol Pathol. 2008 Aug;85(1):68-75. doi: 10.1016/j.yexmp.2008.03.010. Epub 2008 Apr 10.

PMID:
18486128
15.

EGFR mutations and sensitivity to gefitinib.

Rich JN, Rasheed BK, Yan H.

N Engl J Med. 2004 Sep 16;351(12):1260-1; author reply 1260-1. No abstract available.

PMID:
15376352
16.

The genomic landscapes of human breast and colorectal cancers.

Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B.

Science. 2007 Nov 16;318(5853):1108-13. Epub 2007 Oct 11.

17.

Epidermal growth factor receptor mutations in small cell lung cancer.

Tatematsu A, Shimizu J, Murakami Y, Horio Y, Nakamura S, Hida T, Mitsudomi T, Yatabe Y.

Clin Cancer Res. 2008 Oct 1;14(19):6092-6. doi: 10.1158/1078-0432.CCR-08-0332.

18.

Apply innovative technologies to explore cancer genome.

Shih IeM, Wang TL.

Curr Opin Oncol. 2005 Jan;17(1):33-8. Review.

PMID:
15608510
19.

Profiling the cancer genome.

Cowin PA, Anglesio M, Etemadmoghadam D, Bowtell DD.

Annu Rev Genomics Hum Genet. 2010;11:133-59. doi: 10.1146/annurev-genom-082509-141536. Review.

PMID:
20590430
20.

High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets.

Müller-Tidow C, Schwäble J, Steffen B, Tidow N, Brandt B, Becker K, Schulze-Bahr E, Halfter H, Vogt U, Metzger R, Schneider PM, Büchner T, Brandts C, Berdel WE, Serve H.

Clin Cancer Res. 2004 Feb 15;10(4):1241-9.

Supplemental Content

Support Center